Operating profit EBITDA: elevaiskincare.com (ELAB)

Brandmark of Elevai Labs (ELAB)

Elevai Labs Inc. (ELAB) is creating a closed aesthetic medicine ecosystem by connecting physicians and patients through exosome-based beauty solutions. The EBITDA_Co trend clearly demonstrates the inflow of capital into the business, while 0.00 captures the current value of the indicator. The company is actively scaling its line of restorative skin rejuvenation products. Simultaneously, it is implementing ESG standards, including the elimination of microplastics and the use of recycled packaging.

Profit before payment of interest, taxes and amortization: elevaiskincare.com (ELAB) for 11/23/2025 - 11/12/2026

Summary analytical data breakdowns for Elevai Labs (ELAB)

- stock value and consensus price forecast:
Market Chart Elevai Corp|ELAB - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Elevai Labs|ELAB - Enterprise Value
- book value of equity indicators:
Net Assets per Share Elevai Labs|ELAB - Company Book Value|Capitalization to Book Value Ratio elevaiskincare.com|ELAB - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Elevai Labs Inc.|ELAB - Long-Term Debt to Equity|Short-Term Debt to Equity Elevai Labs Inc|ELAB - Company Aggregate Debts|Debts to Book Value Elevai Labs|ELAB - Company Long-Term Liabilities|Company Short-Term Debt Elevai Labs|Quick Ratio elevaiskincare.com
- company profitability and valuation multiples indicators:
ELAB - Net Profit|Company Profit Forecast Elevai Labs Inc.|ELAB - Price to Earnings Ratio|Future Price to Earnings Multiple elevaiskincare.com|ELAB - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Elevai Labs|ELAB - Operating profit EBITDA|Net earnings per share (EPS TTM) Elevai Labs|ELAB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months elevaiskincare.com|ELAB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Elevai Labs Inc.
Summary company analytics:Elevai Labs Inc.
Manufactured product of Elevai Labs Inc

The implementation of ESG standards in skin regeneration biotechnology minimizes waste disposal costs, which directly impacts the calculated value of 0.00. This metric strips the operating cash flow of non-cash charges and accounting adjustments, reflecting the business's actual ability to generate liquidity to cover liabilities, which clearly confirms the absolute EBITDA trend for Elevai Labs Inc. (ELAB).

Competitor analysis for Elevai Labs Inc.

Operating income before deduction of amortization Krystal Biotech Corp. (KRYS)|APGE - Profit before payment of interest, taxes and amortization|ARQT - Operating profit EBITDA|VCEL: Operating profit EBITDA|ORKA - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sanara MedTech, Inc.|Operating profit before amortization DBVT (DBV Technologies SA)|Operating profit EBITDA SLSN|DERM - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Forte Biosciences FBRX|Empro Group Inc. - Profit before payment of interest, taxes and amortization|Sol-Gel - Operating profit EBITDA|Profit before interest, taxes and amortization AXIL Brands, Inc.|MDCX (Medicus Pharma Ltd.) - Operating profit before deduction of amortization|VRCA (Verrica Pharmaceuticals Inc.) - Profit before payment of interest, taxes and amortization|HOTH (Hoth Therapeutics Inc.) - Operating profit EBITDA|Operating profit EBITDA Biofrontera Inc|Operating profit EBITDA VYNE|Operating income before deduction of amortization sonomapharma.com|Quoin Pharmaceuticals Ltd. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AZTR|DRMA - Profit before payment of interest, taxes and amortization|RVNC: Profit before payment of interest, taxes and amortization